Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma

Blood

Volumn 103, Issue 9, 2004, Pages 3529-3534

  Lech Maranda, Ewa ^b   Baseggio, Lucile ^b   Bienvenu, Jacques ^b   Charlot, Carole ^b   Berger, Françoise ^b   Rigal, Dominique ^b   Warzocha, Krzysztof ^b   Coiffier, Bertrand ^b   Salles, Gilles ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; INTERLEUKIN 10; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ALLELE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TREATMENT OUTCOME;

EID: 1942521249     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-1850     Document Type: Article

References (40)

1. Groves FD, Linet MS, Travis LB, et al. Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251.
2. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
3. Swan F, Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7:1518-1527.
4. Caligaris-Cappio F. How immunology is reshaping clinical disciplines: the example of haematology. Lancet. 2001;358:49-55.
5. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol. 2001;19:683-765.
6. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood. 1992;80:1289-1298.
7. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89:1890-1893.
8. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest. 1994;93:424-428.
9. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999;10:433-440.
10. Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993;82:2169-2174.
11. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256-263.
12. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production in meningococcal disease. Lancet. 1997;349:170-173.
13. Kim JM, Brannan CI, Copeland NG, et al. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol. 1992;148:3618-3623.
14. Eskdale J, Kube D, Tesch H, et al. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics. 1997;46:120-128.
15. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenetics. 1997;24:1-8.
16. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphism at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens. 1997;49:635-639.
17. Lim S, Crawley E, Woo P, Barnes P. Haplotype associated with low interleukin-10 production in patients with severe asthma [letter]. Lancet. 1998;352:113.
18. Hulkkonen J, Pertovaara M, Antonen J, et al. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren's syndrome. Arthritis Rheum. 2001;44:176-179.
19. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101-1108.
20. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun. 2000;1:185-190.
21. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018-1026.
22. Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941-3946.
23. Zhu KY, Clark JM. Addition of a competitive primer can dramatically improve the specificity of PCR amplification of specific alleles. Biotechniques. 1996;21:586-590.
24. Coakley G, Mok CC, Hajeer AH, et al. Interelukin-10 promoter polymorhisms in rheumatoid arthritis and Felty's syndrome. Br J Rheumatol. 1998;37:988-991.
25. Bohlen H, Kessler M, Sextro M, et al. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000;79:110-113.
26. Viviani S, Notti P, Bonfante V, et al. Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience. Med Oncol. 2000;17:59-63.
27. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell IL-10: B cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of IL-10. Blood. 1992;80:1289-1298.
28. Emilie D, Touitou R, Raphael M, et al. In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. Eur J Immunol. 1992;22:2937-2942.
29. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 1996;56:5499-5505.
30. Helminen M, Lahdenpohja N, Hurme M. Polymorhism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis. 1999;180:496-499.
31. Socié G, Loiseau P, Tamozua R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001;72:699-706.
32. Perrey C, Pravica V, Sinnott PJ, et al. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1898;6:193-197.
33. Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet. 2000;27:241-249.
34. Mok CC, Lanchbury JS, Chan DW, et al. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1090-1095.
35. Cervenak L, Morbidelli L, Donati D, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interteukin-10. Blood. 2000;96:2568-2573.
36. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol. 1998;60:3188-3193.
37. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol. 1999;162:1723-1729.
38. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor region and non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-3581.
39. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II (HLA DRB1) and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin's lymphoma outcome. Blood. 2002;100:3037-3040.
40. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.